CSPC PHARMA (01093) has received a $30 million upfront payment under the collaboration, option, and licensing agreement with AstraZeneca for the development of siRNA drugs.

date
20:19 12/08/2026
avatar
GMT Eight
Stone Pharmaceuticals Group (01093) announced that the group has entered into a strategic R&D collaboration agreement with AstraZeneca in July 2026 to utilize the group's proprietary siRNA drug discovery platform and extr hepatic targeted delivery platform to develop novel small nucleic acid drug candidates. The board is pleased to announce that, in accordance with the terms of the agreement, the group received a $30 million upfront payment from AstraZeneca on August 12, 2026. The receipt of this upfront payment marks the smooth progression of the collaboration between the two parties, which is beneficial for the group's overall strategic layout and accelerates the development of the small nucleic acid pipeline.
CSPC PHARMA (01093) announced that the group has entered into an agreement with AstraZeneca to establish a strategic R&D collaboration in July 2026, aimed at developing new small nucleic acid candidate drugs using the group's proprietary siRNA drug discovery platform and extra-hepatic targeted delivery platform. The board is pleased to announce that under the terms of the agreement, the group received a $30 million upfront payment from AstraZeneca on August 12, 2026. The receipt of this upfront payment marks a smooth progression in the cooperation between both parties, benefiting the group's overall strategic layout and accelerating the development of the small nucleic acid pipeline.